Granules India reports 23 percent rise in Q3 profit
Granules, which also makes anti-inflammatory drug Ibuprofen, said 45.6 percent of its revenue came from finished dosages, the final ready-for-consumption product - its biggest segment.
Bengaluru: Pharmaceutical company Granules India Ltd, reported a 23 percent rise in third-quarter profit on Tuesday, propelled by strong demand for the painkiller drug Paracetamol.
Consolidated profit rose to 1.24 billion rupees ($15.22 million) for the three months ended Dec. 31, from 1.01 billion rupees a year earlier.
Consolidated revenue for the company rose nearly 15 percent to 11.46 billion rupees, "primarily driven by higher Paracetamol API sales in the US," the company said in an exchange filing.
"Opportunities in Paracetamol are likely to continue, and our geography expansion strategy in Europe is likely to yield higher turnover and EBITDA in future periods," Chairman Krishna Prasad Chigurupati said.
Granules, which also makes anti-inflammatory drug Ibuprofen, said 45.6 percent of its revenue came from finished dosages, the final ready-for-consumption product - its biggest segment.
Active pharmaceutical ingredients and pharmaceutical formulation intermediates contributed 35.8 percent and 18.6 percent, respectively, to the drug manufacturer's revenue.
Shares of the company climbed as much as 1.5 percent to 316.8 rupees, hitting a one-week high after the results. They declined 5.2 percent in 2022, compared with an 11.4 percent fall in the Nifty Pharma index.
Read also: Granules Pharma bags USFDA nod for ADHD drug Amphetamine Mixed Salts ER
Next Story